SD-101
Total Payments
$6.5M
Transactions
26
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $5.5M | 9 | 0 |
| 2018 | $998,929 | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.5M | 26 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) | Dynavax Technologies Corporation | $6.2M | 0 |
| A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Dynavax Technologies Corporation | $248,929 | 0 |
Top Doctors Receiving Payments for SD-101
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Minneapolis, MN | $6.5M | 26 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.5M
- Total Doctors 0
- Transactions 26
About SD-101
SD-101 is a drug associated with $6.5M in payments to 0 healthcare providers, recorded across 26 transactions in the CMS Open Payments database. The primary manufacturer is Dynavax Technologies Corporation.
Payment data is available from 2018 to 2019. In 2019, $5.5M was paid across 9 transactions to 0 doctors.
The most common payment nature for SD-101 is "Unspecified" ($6.5M, 100.0% of total).
SD-101 is associated with 2 research studies, including "I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)" ($6.2M).